Regional Prophylactic Vancomycin in Revision Total Knee Replacement

• Status: Completed
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether or not giving a lower dose of antibiotics (Vancomycin) in the area where it is needed (the knee joint) is more effective at preventing infection than the current standard dose which is given intravenously (IV) through a wrist vein.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Collaborator: Vidacare Corporation
• Treatments: Vancomycin

Criteria

Inclusion Criteria:

• Revision total knee arthroplasty

• Informed consent given

Exclusion Criteria:

• Current treatment with IV Vancomycin within the preceding 7 days

• Previous hypersensitivity to vancomycin

• Significant cardiac or respiratory abnormality

• Contraindications to using the intraosseous vascular access system (EZ-IO)

• Sepsis